CN101703483A - 一种奥美拉唑钠冻干粉针剂及其制备方法 - Google Patents
一种奥美拉唑钠冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN101703483A CN101703483A CN200910226008A CN200910226008A CN101703483A CN 101703483 A CN101703483 A CN 101703483A CN 200910226008 A CN200910226008 A CN 200910226008A CN 200910226008 A CN200910226008 A CN 200910226008A CN 101703483 A CN101703483 A CN 101703483A
- Authority
- CN
- China
- Prior art keywords
- omeprazole
- freeze
- dried powder
- omeprazole sodium
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 78
- 238000002347 injection Methods 0.000 title claims abstract description 61
- 239000007924 injection Substances 0.000 title claims abstract description 61
- 229940063517 omeprazole sodium Drugs 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 title abstract 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 70
- 239000000243 solution Substances 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000008215 water for injection Substances 0.000 claims abstract description 22
- 238000005303 weighing Methods 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 238000000859 sublimation Methods 0.000 claims abstract description 8
- 230000008022 sublimation Effects 0.000 claims abstract description 8
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 71
- 229960000381 omeprazole Drugs 0.000 claims description 71
- RRFCKCAQHRITRG-UHFFFAOYSA-N sodium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide;hydrate Chemical compound O.[Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RRFCKCAQHRITRG-UHFFFAOYSA-N 0.000 claims description 55
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 26
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 5
- 230000009191 jumping Effects 0.000 claims description 5
- 239000010936 titanium Substances 0.000 claims description 5
- 229910052719 titanium Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims 1
- 230000001543 purgative effect Effects 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 14
- 238000012360 testing method Methods 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 238000007710 freezing Methods 0.000 abstract 2
- 230000008014 freezing Effects 0.000 abstract 2
- 238000007670 refining Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 238000011013 endotoxin removal Methods 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- MMJMSRMOAUITKN-UHFFFAOYSA-N 2-sulfinylbenzimidazole Chemical compound C1=CC=CC2=NC(=S=O)N=C21 MMJMSRMOAUITKN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940080130 omeprazole 10 mg Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102260089A CN101703483B (zh) | 2009-11-19 | 2009-11-19 | 一种奥美拉唑钠冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102260089A CN101703483B (zh) | 2009-11-19 | 2009-11-19 | 一种奥美拉唑钠冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101703483A true CN101703483A (zh) | 2010-05-12 |
CN101703483B CN101703483B (zh) | 2011-11-16 |
Family
ID=42373781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102260089A Active CN101703483B (zh) | 2009-11-19 | 2009-11-19 | 一种奥美拉唑钠冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101703483B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512380A (zh) * | 2011-12-20 | 2012-06-27 | 海南锦瑞制药股份有限公司 | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 |
CN102552186A (zh) * | 2012-02-22 | 2012-07-11 | 成都金典药物科技开发有限公司 | 泮托拉唑钠冻干粉针剂及其制备方法 |
CN102871973A (zh) * | 2012-10-16 | 2013-01-16 | 浙江亚太药业股份有限公司 | 一种奥美拉唑钠冻干制剂及其制备方法 |
CN104945380A (zh) * | 2015-06-17 | 2015-09-30 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
CN110946860A (zh) * | 2019-12-30 | 2020-04-03 | 丽珠集团丽珠制药厂 | 一种含有奥美拉唑钠的组合物及其制备方法 |
CN112697688A (zh) * | 2020-12-18 | 2021-04-23 | 正大制药(青岛)有限公司 | 奥美拉唑咀嚼片的耐酸力测定方法 |
CN114028346A (zh) * | 2021-11-19 | 2022-02-11 | 海南皇隆制药股份有限公司 | 注射用奥美拉唑钠及其制备方法 |
-
2009
- 2009-11-19 CN CN2009102260089A patent/CN101703483B/zh active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512380A (zh) * | 2011-12-20 | 2012-06-27 | 海南锦瑞制药股份有限公司 | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 |
CN102512380B (zh) * | 2011-12-20 | 2013-04-17 | 海南锦瑞制药股份有限公司 | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 |
CN102552186A (zh) * | 2012-02-22 | 2012-07-11 | 成都金典药物科技开发有限公司 | 泮托拉唑钠冻干粉针剂及其制备方法 |
CN102871973A (zh) * | 2012-10-16 | 2013-01-16 | 浙江亚太药业股份有限公司 | 一种奥美拉唑钠冻干制剂及其制备方法 |
CN104945380A (zh) * | 2015-06-17 | 2015-09-30 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
WO2016202212A3 (zh) * | 2015-06-17 | 2017-03-09 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
CN110946860A (zh) * | 2019-12-30 | 2020-04-03 | 丽珠集团丽珠制药厂 | 一种含有奥美拉唑钠的组合物及其制备方法 |
CN112697688A (zh) * | 2020-12-18 | 2021-04-23 | 正大制药(青岛)有限公司 | 奥美拉唑咀嚼片的耐酸力测定方法 |
CN114028346A (zh) * | 2021-11-19 | 2022-02-11 | 海南皇隆制药股份有限公司 | 注射用奥美拉唑钠及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101703483B (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703483B (zh) | 一种奥美拉唑钠冻干粉针剂及其制备方法 | |
CN102038648B (zh) | 治疗消化性溃疡的粉针剂及其制备方法 | |
CN101732247B (zh) | 一种含有依达拉奉的注射液 | |
EA022890B1 (ru) | Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения | |
CN102357082A (zh) | 一种埃索美拉唑钠的冻干粉针剂及其制备方法 | |
CN102397245A (zh) | 一种盐酸尼卡地平葡萄糖注射液 | |
CN102285970B (zh) | 一种埃索美拉唑化合物、制备方法及其药物组合物 | |
CN106031710B (zh) | 一种富马酸氟呐普拉赞的注射剂及其制备方法 | |
DE102014008685A1 (de) | Freisetzungssystem für therapeutisches Gas | |
CN100457098C (zh) | 甲磺酸萘莫司他冻干粉针剂及其制备方法 | |
CN104971049B (zh) | 一种含有福沙匹坦的冻干制剂及其制备方法 | |
CN101530392A (zh) | 一种奥美拉唑钠冻干脂质体制剂及其制备方法 | |
CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
CN102973524A (zh) | 一种埃索美拉唑钠冻干粉针剂及其制备方法 | |
CN102796078A (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
CN102670524B (zh) | 一种注射用泮托拉唑钠冻干制剂及其制备方法 | |
CN110269837A (zh) | 盐酸纳洛酮注射液及其制备方法 | |
CN101891751B (zh) | 一种河豚毒素的制备方法 | |
US4698361A (en) | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | |
CN105769756B (zh) | 一种富马酸西他沙星注射剂及其制备方法 | |
CN102871973A (zh) | 一种奥美拉唑钠冻干制剂及其制备方法 | |
CN101716138B (zh) | 一种含有盐酸替罗非班的注射液 | |
CN101708179B (zh) | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 | |
CN102100695B (zh) | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 | |
CN100389764C (zh) | 一种含硫普罗宁的冻干组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 570216 standard workshop No. 1, American industrial village, 100 Nanhai Road, Haikou, Hainan Patentee after: HAINAN BEITE PHARMACEUTICAL Co.,Ltd. Address before: 570216 standard workshop No. 1, American industrial village, 100 Nanhai Road, Haikou, Hainan Patentee before: HAINAN LEVTEC PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Omeprazole sodium lyophilized powder injection and its preparation method Effective date of registration: 20220719 Granted publication date: 20111116 Pledgee: Bank of Hainan Limited by Share Ltd. Pledgor: HAINAN BEITE PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980010815 |